Springboard Health Angels, Pluton Asset Holding AG, Sintra Limited, and Technologiegründerfonds Sachsen joined as new investors
Existing investors i&i Biotech Fund I SCSp, HIL-INVENT and Brandenburg Kapital also participated in the round
Schoenefeld/Berlin, Germany, November 17, 2025 --- Captain T Cell, a biotechnology company developing next-generation TCR-T cell therapies for solid tumors, today announced the successful closing of an equity financing round with both new and existing investors. The latest equity funding, along with already secured grants, provides Captain T Cell with a total budget of EUR 20 million to advance its best-in-class autologous program CTC127 to clinical Phase I read-outs and its first-in-class allogeneic program for off-the-shelf solid tumor treatments towards clinical trial readiness.
The round was led by Springboard Health Angels and Pluton Asset Holding AG, joined by Sintra Limited and Technologiegründerfonds Sachsen, as well as existing investors i&i Biotech Fund, HIL-INVENT and Brandenburg Kapital.
The funds will enable the Company´s lead program CTC127 to progress into a first-in-human Phase I clinical trial (TOMATA - "Toolbox-modified MAGE-A4-TCR-T cell therapy for HLA-A1"). The trial will be led by principal investigator Prof. Antonia Busse, Charité, Universitaetsmedizin Berlin, with participation from eight other leading cancer centers across Germany. The study will enroll patients with multiple advanced MAGE-A4-positive solid tumor indications, including lung, bladder, gastroesophageal, ovarian, and head and neck cancers. CTC127 is based on the Company's proprietary and versatile engineering toolbox, which enables functional "armoring" of T cells to enhance their anti-tumor activity, persistence, and resilience within the solid tumor microenvironment.
In parallel, the Company has already demonstrated complete solid tumor responses in vivo with a program leveraging its first-in-class allogeneic TCR-T cell platform and will advance it toward clinical trial readiness. Furthermore, the Company plans to extend its proprietary best-in-class toolbox towards in vivo T cell therapy applications.
"Despite a challenging fundraising environment, we have gained broad investor support, which underscores the strong competitive profile of Captain T Cell's best- and first-in-class next-generation T cell therapy platform and enables us to advance these therapies for the benefit of cancer patients," said Dr. Felix Lorenz, CEO of Captain T Cell. "Our best-in-class autologous program CTC127 will enter the fully funded TOMATA clinical trial and our first-in-class allogeneic TCR-T platform is progressing toward clinical readiness. We are optimistic that our best-in-class toolbox technologies will be clinically validated in the upcoming trial and subsequently expanded into off-the-shelf approaches."
"We are excited to co-lead this recent financing round of Captain T Cell," said Dr. Andreas Schmidt of Springboard Health Angels. "The Company´s lead program CTC127 holds the potential to become a highly effective and safe therapy for solid tumor patients who urgently need novel treatment options. With funding ...
